170 related articles for article (PubMed ID: 36949660)
1. Donor Selection for Allogeneic Hematopoietic Cell Transplantation.
Fleischhauer K; Tran TH; Meisel R; Mytilineos J; Dreger P; Kröger N
Dtsch Arztebl Int; 2023 Apr; 120(15):261-268. PubMed ID: 36949660
[TBL] [Abstract][Full Text] [Related]
2. Current donor selection strategies for allogeneic hematopoietic cell transplantation.
Timofeeva OA; Philogene MC; Zhang QJ
Hum Immunol; 2022 Oct; 83(10):674-686. PubMed ID: 36038413
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bashey A; Solomon SR
Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
7. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Nath K; Lee J; Elko TA; Levy L; Preston E; Devlin SM; Ponce DM; Lin RJ; Shaffer BC; Cho C; Politikos I; Jakubowski AA; Park JH; Rampal R; Perales MA; Tallman MS; Barker JN; Berman E; Tamari R; Stein E; Giralt SA; Gyurkocza B
Am J Hematol; 2023 Dec; 98(12):1869-1876. PubMed ID: 37688521
[TBL] [Abstract][Full Text] [Related]
8. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
9. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT.
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Ciceri F; Finke J; Bruno B; Bornhäuser M; Gedde-Dahl T; Labussière-Wallet H; Niittyvuopio R; Valerius T; Angelucci E; Brecht A; Caballero D; Kuball J; Potter V; Schmid C; Tischer J; Zuckerman T; Benedetti F; Blaise D; Diez-Martin JL; Sanz J; Ruggeri A; Brissot E; Savani BN; Giebel S; Nagler A; Mohty M
Bone Marrow Transplant; 2021 Sep; 56(9):2194-2202. PubMed ID: 33931757
[TBL] [Abstract][Full Text] [Related]
10. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
12. Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia.
Pearce KF; Lee SJ; Haagenson M; Petersdorf EW; Norden J; Collin MP; Klein JP; Spellman SR; Lowerson SA; Davies S; Dickinson AM
Haematologica; 2012 Jul; 97(7):1014-9. PubMed ID: 22271889
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
14. Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida.
Horn B; Lamba N; Chellapandian D; Sunkersett G; Silva JG; Ziga E; Alperstein W; Joyce M; Castillo P; Fort J; Zhao J; Oshrine B
Pediatr Blood Cancer; 2021 Oct; 68(10):e29180. PubMed ID: 34121322
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
Pidala J; Lee SJ; Ahn KW; Spellman S; Wang HL; Aljurf M; Askar M; Dehn J; Fernandez Viña M; Gratwohl A; Gupta V; Hanna R; Horowitz MM; Hurley CK; Inamoto Y; Kassim AA; Nishihori T; Mueller C; Oudshoorn M; Petersdorf EW; Prasad V; Robinson J; Saber W; Schultz KR; Shaw B; Storek J; Wood WA; Woolfrey AE; Anasetti C
Blood; 2014 Oct; 124(16):2596-606. PubMed ID: 25161269
[TBL] [Abstract][Full Text] [Related]
17. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
18. Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome.
Vazirabad I; Chhabra S; Nytes J; Mehra V; Narra RK; Szabo A; Jerkins JH; Dhakal B; Hari P; Anderson MW
Biol Blood Marrow Transplant; 2019 May; 25(5):921-931. PubMed ID: 30537549
[TBL] [Abstract][Full Text] [Related]
19. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
[TBL] [Abstract][Full Text] [Related]
20. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
